Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TOP1 | P11387 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3391749 | 1.00 | LMNA (0.69) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL193773 | 1.00 | LMNA (0.69) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL309466 | 1.00 | LMNA (0.69) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL13134752 | 1.00 | LMNA (0.69) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL3392184 | 1.00 | LMNA (0.69) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL15459817 | 1.00 | LMNA (0.69) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL600061 | 1.00 | LMNA (0.69) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL1017001 | 1.00 | LMNA (0.69) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL22128527 | 1.00 | LMNA (0.69) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL307897 | 1.00 | LMNA (0.69) | LMNAL3MBTL1TDP1KDM4EPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139192-A1 | SUSTAINABLE FUEL COMPOSITIONS AND METHODS OF MAKING THE SAME | SAFION RENEWABLES INC (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026107384-A2 | SUSTAINABLE FUEL COMPOSITIONS AND METHODS OF MAKING THE SAME | SAFION RENEWABLES INC. (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260139282-A1 | LACTONE COMPOSITIONS AND METHODS OF MAKING THE SAME | SAFION RENEWABLES INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20230193336-A1 | ENASIDENIB GLYCOSIDES AND METHODS OF TREATING DISEASES ASSOCIATED WITH ISOCITRATE DEHYDROGENASE (IDH) DYSFUNCTION | DOUBLERAINBOW BIOSCIENCES INC. | 2023-06-22 | — | — | US | claimed |
| US-20230192748-A1 | Etoposide Glycosides, Methods Of Making, And Uses Thereof As An Anti-Cancer Drug | DOUBLERAINBOW BIOSCIENCES INC. | 2023-06-22 | — | — | US | claimed |
| US-20230124589-A1 | Ivacaftor Glycosides, Methods Of Making, And Uses Thereof In Treating Cystic Fibrosis | DOUBLERAINBOW BIOSCIENCES INC. | 2023-04-20 | — | — | US | claimed |
| EP-4121546-A1 | ETOPOSIDE GLYCOSIDES, METHODS OF MAKING, AND USES THEREOF AS AN ANTI-CANCER DRUG | Doublerainbow Biosciences Inc. (US) | 2023-01-25 | — | — | EP | claimed |
| WO-2021188457-A1 | ETOPOSIDE GLYCOSIDES, METHODS OF MAKING, AND USES THEREOF AS AN ANTI-CANCER DRUG | DOUBLERAINBOW BIOSCIENCES INC. (US) | 2021-09-23 | — | — | WO | claimed |
| WO-2021188456-A1 | ENASIDENIB GLYCOSIDES AND METHODS OF TREATING DISEASES ASSOCIATED WITH ISOCITRATE DEHYDROGENASE (IDH) DYSFUNCTION | DOUBLERAINBOW BIOSCIENCES INC. (US) | 2021-09-23 | — | — | WO | claimed |
| WO-2021188459-A1 | IVACAFTOR GLYCOSIDES, METHODS OF MAKING, AND USES THEREOF IN TREATING CYSTIC FIBROSIS | DOUBLERAINBOW BIOSCIENCES INC. (US) | 2021-09-23 | — | — | WO | claimed |
| US-20180201571-A1 | OILS HAVING ANTIBACTERIAL ACTIVITY | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE | 2018-07-19 | — | — | US | claimed |
| US-9950986-B2 | Oils having antibacterial activity | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 2018-04-24 | — | — | US | claimed |
| US-20170281772-A1 | A NEURAL SUBSTRATE FOR SUGAR PREFERENCE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-10-05 | — | — | US | claimed |
| US-20170050916-A1 | NOVEL OILS HAVING ANTIBACTERIAL ACTIVITY | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE | 2017-02-23 | — | — | US | claimed |
| EP-2096164-B1 | MICROORGANISM CAPABLE OF PRODUCING DEOXY POLYOL DEHYDROGENASE AND UTILIZATION OF THE SAME | UNIV KAGAWA NAT UNIV CORP (JP) | 2016-05-11 | — | — | EP | claimed |
| WO-2015142736-A1 | NOVEL OILS HAVING ANTIBACTERIAL ACTIVITY | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 2015-09-24 | — | — | WO | claimed |
| US-8530222-B2 | Microorganism with ability to produce deoxy polyol dehydrogenase and use thereof | NATIONAL UNIVERSITY CORPORATION KAGAWA UNIVERSITY (JP) | 2013-09-10 | — | — | US | claimed |
| US-20100167350-A1 | MICROORGANISM WITH ABILITY TO PRODUCE DEOXY POLYOL DEHYDROGENASE AND USE THEREOF | NAT'L UNIVERSITY CORPORATION KAGAWA UNIVERSITY (JP) | 2010-07-01 | — | — | US | claimed |
| EP-2096164-A1 | MICROORGANISM CAPABLE OF PRODUCING DEOXY POLYOL DEHYDROGENASE AND UTILIZATION OF THE SAME | National University Corporation Kagawa University (JP) | 2009-09-02 | — | — | EP | claimed |
| US-5521160-A | COMPOUNDS FOR TREATMENT OF ATHERIOSCLEROSIS IN BLOOD VESSELS AND PREVENTION OF RESTENOSIS AFTER ANGIOPLASTY | HOFFMANN-LA ROCHE INC. (US) | 1996-05-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230124589-A1 | Ivacaftor Glycosides, Methods Of Making, And Uses Thereof In Treating Cystic Fibrosis | UGGT1, UGDH, GALE | LMNA 3103/4885L3MBTL1 1359/4885TDP1 3143/4885 |
| US-20180201571-A1 | OILS HAVING ANTIBACTERIAL ACTIVITY | AGL, DAGLA, DAGLB | LMNA 755/4885L3MBTL1 49/4885TDP1 1157/4885 |
| US-20260139192-A1 | SUSTAINABLE FUEL COMPOSITIONS AND METHODS OF MAKING THE SAME | DAGLA, DAGLB, AGL | LMNA 598/4885L3MBTL1 1210/4885TDP1 2698/4885 |
| US-20230193336-A1 | ENASIDENIB GLYCOSIDES AND METHODS OF TREATING DISEASES ASSOCIATED WITH ISOCITRATE DEHYDROGENASE (IDH) DYSFUNCTION | UGDH, IDH1, G6PD | LMNA 3336/4885L3MBTL1 1574/4885TDP1 949/4885 |
| US-20230192748-A1 | Etoposide Glycosides, Methods Of Making, And Uses Thereof As An Anti-Cancer Drug | GALE, UGGT1, DERA | LMNA 2057/4885L3MBTL1 1063/4885TDP1 525/4885 |
| US-20100167350-A1 | MICROORGANISM WITH ABILITY TO PRODUCE DEOXY POLYOL DEHYDROGENASE AND USE THEREOF | DCXR, SI, SORD | LMNA 2276/4885L3MBTL1 1064/4885TDP1 1591/4885 |
| US-20170050916-A1 | NOVEL OILS HAVING ANTIBACTERIAL ACTIVITY | DAGLA, DAGLB, AGL | LMNA 830/4885L3MBTL1 41/4885TDP1 1030/4885 |
| US-20260139282-A1 | LACTONE COMPOSITIONS AND METHODS OF MAKING THE SAME | LIPA, CUTA, ALOX5 | LMNA 2043/4885L3MBTL1 3355/4885TDP1 4612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.